Developed by ProMetic’s subsidiary ProMetic Biosciences, Mimetic Ligand affinity adsorbent is expected to be supplied in the third and fourth quarters of 2011.
Further, the supply agreement allows ProMetic to supply a purification component to the client in the event of any manufacturing scale-up of the biopharmaceutical product in anticipation of regulatory approval and market launch.
ProMetic president and CEO Pierre Laurin said repeat orders from client underscore the company’s ability to consistently meet its clients’ large scale present and future manufacturing process needs.